mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制研究

doi:10.3969/j.issn.1004-616x.2020.06.007

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (6): 448-451.doi: 10.3969/j.issn.1004-616x.2020.06.007

mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制研究

林凯煌¹, 蔡高阳¹, 刘新城²

1. 汕头大学医学院第二附属医院胃肠外科, 广东汕头 515065;
2. 汕头大学医学院第二附属医院泌尿外科, 广东汕头 515065

收稿日期:2020-05-07 修回日期:2020-10-18 出版日期:2020-12-01 发布日期:2020-12-04
通讯作者: 刘新城,E-mail:liuxincheng321@163.com E-mail:liuxincheng321@163.com
作者简介:林凯煌,E-mail:linkaihuang@163.com。
基金资助:
广东省医学科学技术研究基金（B2018267）

Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells

LIN Kaihuang¹, CAI Gaoyang¹, LIU Xincheng²

1. Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515065;
2. Department of Durological Surgery, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515065, Guangdong, China

Received:2020-05-07 Revised:2020-10-18 Online:2020-12-01 Published:2020-12-04

摘要/Abstract

摘要： 目的：初步探讨mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制。方法：先采用CCK-8法检测不同浓度的AZD2014（10、100、500、1 000 nmol/L）对肝癌细胞增殖的作用，再分别采用荧光定量PCR和Western blot法检测肝癌细胞中含植物同源结构和环指域泛素样蛋白1（UHRF1）mRNA和蛋白的表达水平。结果：细胞增殖实验结果显示，10、100、500、1 000 nmol/L的AZD2014均可显著抑制肝癌细胞的增殖能力，抑制程度与其浓度呈正相关（P < 0.05）；荧光定量PCR和Western blot检测结果显示，500和1 000 nmol/L的AZD2014可显著降低肝癌细胞内UHRF1 mRNA及蛋白的表达水平。结论：AZD2014可能通过抑制肝癌细胞内UHRF1的表达水平来抑制肝癌细胞的增殖能力。

关键词: mTOR抑制剂, AZD2014, 含植物同源结构和环指域泛素样蛋白1, 肝细胞癌, 增殖抑制作用

Abstract: OBJECTIVE: To investigate the effect of mTOR inhibitor,AZD2014,on proliferation of HCC cells. METHODS: The CCK-8 method was used to detect proliferation of HCC cells after their treatment with different concentrations of AZD2014 (10,100,500,1 000 nmol/L). Expression levels of UHRF1 mRNA and protein were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western Blot,respectively. RESULTS: The CCK-8 results show that different concentrations of AZD2014 (10,100,500,1 000 nmol/L) significantly inhibited proliferation of hepatoma cells,and the degree of inhibition was positively dose-dependent. In addition,the RT-PCR and Western Blot data show that AZD2014 at concentrations of 500 nmol/L and 1 000 nmol/L reduced the expression of UHRF1 mRNA and protein in HCC cells. CONCLUSION: AZD2014 inhibited proliferation of HCC cells by repressing expression of UHRF1.

Key words: mTOR inhibitor, AZD2014, UHRF1, hepatocellular carcinoma, proliferation inhibition

中图分类号:

R735.7

林凯煌, 蔡高阳, 刘新城. mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制研究[J]. 癌变·畸变·突变, 2020, 32(6): 448-451.

LIN Kaihuang, CAI Gaoyang, LIU Xincheng. Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 448-451.

参考文献

[1] KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2):477-491.
[2] RICH N E, PARIKH N D, SINGAL A G. Hepatocellular carcinoma and liver transplantation:changing patterns and practices[J]. Curr Treat Options Gastroenterol, 2017, 15(2):296-304.
[3] LIAO M, ZHONG X, ZHANG J, et al. Radiofrequency ablation using a 10-mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis:a prospective randomized trial[J]. J Surg Oncol, 2017, 115(8):971-979.
[4] GE S H, HUANG D Z. Systemic therapies for hepatocellular carcinoma[J]. Drug Discov Ther, 2015, 9(5):352-362.
[5] CHOI K J, BAIK I H, YE S K, et al. Molecular targeted therapy for hepatocellular carcinoma:present status and future directions[J]. Biol Pharm Bull, 2015, 38(7):986-991.
[6] LIAO H, HUANG Y, GUO B, et al. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma[J]. Am J Cancer Res, 2015, 5(1):125-139.
[7] POWLES T, WHEATER M, DIN O, et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer[J]. Eur Urol, 2016, 69(3):450-456.
[8] WANG C, WANG X, SU Z, et al. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth[J]. Oncol Rep, 2015, 34(4):1708-1716.
[9] FASOLO A, SESSA C. Targeting mTOR pathways in human malignancies[J]. Curr Pharm Des, 2012, 18(19):2766-2777.
[10] AL-BATRAN S E, DUCREUX M, OHTSU A. mTOR as a therapeutic target in patients with gastric cancer[J]. Int J Cancer, 2012, 130(3):491-496.
[11] ZONCU R, EFEYAN A, SABATINI D M. mTOR:from growth signal integration to cancer, diabetes and ageing[J]. Nat Rev Mol Cell Biol, 2011, 12(1):21-35.
[12] SARBASSOV D D, GUERTIN D A, ALI S M, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J]. Science, 2005, 307(5712):1098-1101.
[13] GUERTIN D A, SABATINI D M. Defining the role of mTOR in cancer[J]. Cancer Cell, 2007, 12(1):9-22.
[14] VILLANUEVA A, CHIANG D Y, NEWELL P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(6):1972-1983.
[15] PENG X G, ZHANG D H, LI Z L, et al. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat[J]. Biochem Biophys Res Commun, 2016, 477(4):556-562.
[16] MILOŠEVIĆ Z, BANKOVIĆ J, DINIĆ J, et al. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma[J]. Cell Oncol (Dordr), 2018, 41(4):409-426.
[17] FUJIMORI A, MATSUDA Y, TAKEMOTO Y, et al. Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation[J]. Mamm Genome, 1998, 9(12):1032-1035.
[18] HASHIMOTO H, HORTON J R, ZHANG X, et al. UHRF1, a modular multi-domain protein, regulates replication-coupled crosstalk between DNA methylation and histone modifications[J]. Epigenetics, 2009, 4(1):8-14.
[19] ZHANG Y, HUANG Z, ZHU Z, et al. Upregulated UHRF1 promotes bladder cancer cell invasion by epigenetic silencing of KiSS1[J]. PLoS One, 2014, 9(10):e104252.
[20] LIU X, OU H, XIANG L, et al. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(6):10510-10522.

mTOR抑制剂AZD2014对肝癌细胞的增殖抑制作用及其机制研究

Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[2]	彭威, 邱氟. 跨膜4超家族成员1在原发性肝细胞癌组织中的表达及其对患者预后的影响[J]. 癌变·畸变·突变, 2017, 29(6): 427-430,436.
[3]	刘德忠, 常波, 林飞翔, 李学东. β-catenin在肝癌组织中的表达及对肝癌患者预后的影响[J]. 癌变·畸变·突变, 2017, 29(4): 300-303.
[4]	李超, 倪娟, 徐伟江, 汪旭. miR-22、miR-34a与叶酸介导的一碳代谢在非小细胞肺癌和肝细胞癌中的调控作用[J]. 癌变·畸变·突变, 2016, 28(4): 317-320.
[5]	牛永东，陈理明，吴曼鹏，程訸，徐涵，高分飞，石刚刚. 慢病毒介异的孕烷X受体sh-RNA稳定干扰HepG2细胞株的构建[J]. 癌变·畸变·突变, 2014, 26(3): 209-212.
[6]	梁晓芸，李文学，陈建玲，李军涛，吴锦银，杨光宇，朱伟. 玻连蛋白促进肝癌细胞株增殖及迁移的初步研究[J]. 癌变·畸变·突变, 2014, 26(1): 30-34.
[7]	程龙强1;章尧2;陈昌杰2;杨清玲2;王惠1. 肝细胞癌中载脂蛋白M，肝受体同系物1和肝细胞核因子1α表达的相关性分析[J]. , 2010, 22(2): 130-133.
[8]	邱历伟，姚登福，姜　华，李月明，赛文莉，袁菊萍，吴　玮，吴信华. 肝细胞癌变过程中缺氧诱导因子-1α的动态表达与改变特征[J]. , 2009, 21(1): 10-014.
[9]	夏　俊;陈俊霞;于丽华;崔秀云. 三氧化二砷抑制人膀胱癌EJ细胞增殖及其作用机制探讨[J]. , 2005, 17(3): 160-162.
[10]	杨连君, 王文亮. 基因转染法建立bcl-2 稳定表达的肝癌细胞株[J]. , 2001, 13(2): 92-095.
[11]	盖晓东,李国利,王琰,董志恒. 肝细胞癌P53 蛋白的表达及临床意义的研究[J]. , 2000, 12(2): 93-094.